NCT07107178

A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

A Phase Ib Study of the Safety, Tolerability and Efficacy of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 58 (estimated)
• Sponsor: Biotroy Therapeutics · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with advanced melanoma,regardless of gender, aged between 18 and 75 years (inclusive). Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.

Conditions

• Advanced Melanoma
• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	BT02	monoclonal antibody injection with intravenous administration every 2 or 3 weeks

Timeline

• Start date: 2025-08-08
• Primary completion: 2027-05-01
• Completion: 2027-08-01
• First posted: 2025-08-06
• Last updated: 2025-08-06

Regulatory

• FDA-regulated drug study